Netherlands Archives

Interview 25 Sep 2017

Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model

Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the agricultural university in Wageningen, The Netherlands, when “I got fascinated by molecular biology, and the biotech industry in […]

September 25, 2017 - 10 minutesmins - By Evelyn Warner

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

GARDP Antibiotic Resistance Europe Germany

News and Trends 6 Sep 2017

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

argenx staten biotechnology dyslipidemia

More News! 23 Aug 2017

Dutch Biotech could treat Dyslipidemia with Belgian Nanobody

Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and backed by BioGeneration Ventures and Forbion Capital Partners as investors. Back […]

August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Jul 2017

Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease

Pharming has published Phase II data in The Lancet supporting its lead candidate as a treatment for the rare genetic disease hereditary angioedema. Pharming, one of the top biotechs in Leiden, specializes in recombinant protein technology. Its lead compound, ruconest, is a recombinant human C1 inhibitor protein. The results of a 32-patient Phase II study published […]

July 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

genetically modified mosquitoes Oxitec Netherlands

News and Trends 12 Jul 2017

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will help shape the policy to regulate the genetically engineered insects in France and eventually allow testing the technology in the French Caribbean. Originally published on 07/07/2017 A […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Scenic Biotech Genetic Off Switch Cancer Rare Disease

News and Trends 5 Jun 2017

New Dutch Biotech Gets Funding to Find Genetic Off Switches

Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […]

June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 8 May 2017

Meet the co-developer of the first commercial mAb and gene therapy

Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […]

May 8, 2017 - 5 minutesmins - By Philip Hemme

Startup Scout 28 Apr 2017

This Dutch Biotech Could Boost Gene Editing of Primary Cells

Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in 2015 based on a cutting-edge intracellular delivery technology developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. Mission: NTrans is developing the iTOP technology for its use in research and as a therapeutical platform for the delivery of bioactive molecules into […]

April 28, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us